10-Q: Immunome Reports Q1 2026 Financials, Advances Pipeline

Immunome, Inc. reported its first-quarter 2026 financial results, highlighting continued investment in its oncology pipeline and a strong cash position.

Summary

• Immunome, Inc. reported a net loss of $53.8 million for the three months ended March 31, 2026, compared to a net loss of $41.6 million for the same period in 2025.
• Research and development expenses increased to $46.4 million from $36.9 million year-over-year, driven by increased clinical trial activities for IM-1021, IM-3050, and IM-1617, as well as IND-enabling activities for other candidates.
• General and administrative expenses rose to $13.0 million from $10.7 million, primarily due to increased personnel costs and share-based compensation.
• Interest income increased to $5.5 million from $3.0 million, benefiting from higher cash balances.
• The company ended the quarter with $582.7 million in cash and cash equivalents.
• Varegacestat (formerly AL102) submitted an NDA in April 2026 and plans an MAA submission in Europe by year-end 2026.
• IM-1021 (ROR1 ADC) is in Phase 1 trials, with initial lymphoma data expected in 2026.
• IM-3050 (FAP RLT) initiated Phase 1 trials in March 2026.
• IM-1617 (ADC) received IND clearance in April 2026, with Phase 1 trials planned for Q2 2026.
• Two preclinical solid tumor ADCs, IM-1340 and IM-1335, are expected to have IND submissions in mid-2026 and late 2026, respectively.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While the company continues to advance its promising pipeline and maintains a strong cash position, the increased net loss and operating expenses indicate significant ongoing investment without immediate revenue generation, which is typical for the biotech sector but presents a negative short-term financial outlook.

Positives

• Strong cash position of $582.7 million as of March 31, 2026, providing at least 12 months of operating runway.
• Successful submission of an NDA for varegacestat in April 2026.
• Initiation of Phase 1 trials for IM-3050.
• IND clearance for IM-1617, with Phase 1 trials planned for Q2 2026.
• Continued progress in advancing multiple clinical and preclinical oncology assets.
• Increased interest income to $5.5 million, reflecting higher cash balances.

Negatives

• Increased net loss of $53.8 million for the quarter, up from $41.6 million in the prior year period.
• Higher research and development expenses ($46.4 million vs. $36.9 million) due to increased clinical trial activities.
• Higher general and administrative expenses ($13.0 million vs. $10.7 million) due to increased headcount and share-based compensation.
• No collaboration revenue recognized in the current quarter, as the AbbVie agreement terminated in July 2025.

Risks

• The company has a history of losses and expects to continue incurring significant losses for the foreseeable future, with no guarantee of achieving profitability.
• The company has a limited operating history, making it difficult to evaluate its drug development capabilities and predict future performance.
• There is a risk of failure in advancing product candidates through clinical development, obtaining regulatory approvals, and commercializing them.
• Competition in the oncology therapeutic market is substantial, with potential for competitors to develop or commercialize products more quickly or successfully.
• The company relies on third-party contract manufacturers for production, and any supply limitations or interruptions could adversely affect its business.
• The market price of common stock is expected to be volatile, and purchasers could incur substantial losses.
• Future sales of common stock could result in dilution to existing stockholders.
• The company's ability to use net operating loss carryforwards may be limited by ownership changes.
• The company is subject to stringent and evolving data privacy and security laws and regulations.
• Changes in healthcare legislation and regulations, including pricing and reimbursement policies, could materially affect the business.
• The company's reliance on intellectual property protection is critical, and challenges to patents or failure to secure adequate protection could harm its business.
• The company may face difficulties in attracting and retaining qualified key personnel.
• The company's operations are concentrated in one location, making it vulnerable to natural disasters or other disruptions.

Future Outlook

The company expects its existing cash and cash equivalents as of March 31, 2026, to be sufficient to fund its current and planned operating expenses and capital expenditures for at least 12 months from the filing date. However, additional financing will be required to support ongoing operations and pursue its research and development strategy and commercialization of varegacestat, if approved.

Management Comments

• Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients.
• We are advancing a pipeline that includes four clinical assets and two preclinical assets.
• Our approach to discovery centers on designing ADCs against novel or underexplored targets, which we believe provides a path to significant clinical benefit and meaningful market opportunities.
• We believe that combining novel targets with a broad toolbox of linkers and payloads supports our mission to design and develop a diverse pipeline of ADCs that address unmet medical need.

Industry Context

StockSavvy.ai notes that Immunome's focus on targeted oncology therapies, particularly antibody-drug conjugates (ADCs) and radioligand therapies (RLTs), aligns with significant trends in the biopharmaceutical industry. The company's pipeline progression, including the NDA submission for varegacestat, demonstrates active development in a highly competitive but promising therapeutic area.

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• The company's ability to commercialize products depends on third-party payors and government reimbursement policies, impacting potential revenue and shareholder value.
• Employees' continued service is critical for the company's success; loss of key personnel could negatively impact operations.

Next Steps

• Submit a marketing authorization application (MAA) with the European Medicines Agency (EMA) for varegacestat by the end of 2026.
• Present initial lymphoma data for IM-1021 in 2026.
• Initiate a Phase 1 trial for IM-1617 in the second quarter of 2026.
• Submit an IND for IM-1340 in mid-2026.
• Submit an IND for IM-1335 in late 2026.

Key Dates

Recommendation

Immunome is a clinical-stage biotechnology company with a promising pipeline in oncology. The company has a strong cash position, which provides runway for at least 12 months. However, the increased net loss and operating expenses, typical for the sector, coupled with the lack of immediate revenue, warrant a cautious approach. The successful development and commercialization of its pipeline assets, particularly varegacestat, will be key drivers for future value. Investors should monitor clinical trial progress, regulatory approvals, and future financing activities.

Keywords

Immunome, 10-Q, Biotechnology, Oncology, ADC, Clinical Trials, Varegacestat, IM-1021, IM-3050, Financial Results, SEC Filing